Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itopride in MAFLD
NCT05966025Phase 2Not yet recruiting
- Sponsor
- October 6 University
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of itopride in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by October 6 University. Primary endpoint: Incidence of MAFLD at 1 Year. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
itopride
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT05966025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966025.